Thursday, January 27, 2022   fundraising

Ractigen Therapeutics closes an additional $30 million in Series A+ funding to push development of its RNAa platform

[01/27/2022, Nantong] Ractigen Therapeutics today announced the closing of a Series A+ financing round totaling $30 million led...

News

Wednesday, February 10, 2021

Ractigen Therapeutics closes on $17 Million Series A to advance lead program into clinical phase, led by Hillhouse Venture Capital

[2/11/2021, Nantong] Ractigen Therapeutics, a leading company in the saRNA drug space, announced that it has closed a 17$ million USD (¥110 million) Series A financing round led by Hillhouse Venture Capital with participation from CCB Healthcare Growth Fund, Boyi Capital, and Longman Capital to support advancement of its lead ph

Wednesday, October 11, 2017

Ractigen Therapeutics CSO Dr. Robert Place delivers a keynote speech at the 6th RNAi China conference

The 6th RNAi China conference was held on October 10th and 11th at Kunshan as expected. A host of leading experts in the fields of oligonucleotide research and drug development from both academia and industry including Ractigen Therapeutics’s CEO Dr.

Wednesday, July 12, 2017

The first book on RNAa published

Springer•Nature published a book edited by Ractigen’s founder, Dr. Long-Cheng LI and entitled “RNA Activation”. This is the first published book on RNAa and was contributed by over 40 worldwide experts working on RNAa.